Legacy Capital Wealth Partners LLC Sells 64 Shares of Eli Lilly and Company (NYSE:LLY)

Legacy Capital Wealth Partners LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 10.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 531 shares of the company’s stock after selling 64 shares during the quarter. Legacy Capital Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $310,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Lipe & Dalton bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $26,000. Thompson Investment Management Inc. purchased a new stake in Eli Lilly and Company during the third quarter worth $27,000. Legacy Financial Group LLC bought a new stake in Eli Lilly and Company during the 3rd quarter valued at $35,000. Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $36,000. Finally, Family CFO Inc bought a new position in shares of Eli Lilly and Company in the 3rd quarter worth $40,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Up 0.5 %

NYSE:LLY opened at $737.33 on Tuesday. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The company’s fifty day moving average price is $760.89 and its 200-day moving average price is $668.00. Eli Lilly and Company has a 1-year low of $392.26 and a 1-year high of $800.78. The firm has a market capitalization of $700.58 billion, a P/E ratio of 127.13, a PEG ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period last year, the firm earned $2.09 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current year.

Wall Street Analyst Weigh In

LLY has been the topic of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research note on Monday, April 15th. Bank of America boosted their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.